FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / Heterologous Wharton’s Jelly Derived Mesenchymal Stem ...
Frontiers in veterinary science2019; 6; 9; doi: 10.3389/fvets.2019.00009

Heterologous Wharton’s Jelly Derived Mesenchymal Stem Cells Application on a Large Chronic Skin Wound in a 6-Month-Old Filly.

Abstract: A complex feedback of growth factors, secreted by a variety of cell types, is responsible for the mediation of skin healing. Despite the recent advances in wound healing management, this fails up to 50% and skin wounds can still be considered one of the main causes of morbidity, both in human and veterinary medicine. Regenerative medicine, involving mesenchymal stromal cells (MSCs), is nowadays a promising solution for skin wound healing. Indeed, MSCs are involved in the modulation of the inflammatory local response and cell replacing, by a paracrine mode of action. Local application of equine umbilical cord Wharton's jelly MSCs (WJMSCS) was carried out in a 6-months-old filly with a non-healing skin wound. Heterologous WJMSCs were applied four times using a carboxymethylcellulose (CMC) gel, produced dissolving CMC in autologous plasma. At first application the mean wound area was 7.28 ± 0.2 cm2. Four days after the last application of WJMSCs, the mean wound area was 1.90 ± 0.03 cm2, and the wound regression rate was +74%. No local or systemic side effects were registered after WJMSCs application and no evident exuberant scar was observed after wound healing. At discharge, the mean wound area was 0.38 ± 0.01 cm2 and the total regression rate was +80%. Five days later, the wound was completely healed. In the present clinical case report, the use of WJMSCs led to promising clinical results, paving the way for possible future applications in the treatment of chronic wounds in horses.
Get Full Text
Publication Date: 2019-01-30 PubMed ID: 30761313PubMed Central: PMC6363668DOI: 10.3389/fvets.2019.00009Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Case Reports
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigated the use of a specific type of stem cells (Wharton’s Jelly Derived Mesenchymal Stem Cells) to treat a large chronic skin wound in a 6-month-old filly. The findings suggest that these stem cells can significantly improve wound healing rates, reducing wound size by an average of 74% shortly after treatment and by 80% at discharge, with no observed side effects.

Understanding the Research

  • The basis for the study is related to the complex network of growth factors secreted by different types of cells, which influence the healing of skin wounds. Despite advances in the management of wound healing, up to half of these attempts are unsuccessful. Skin wounds remain a significant cause of illness in both human and veterinary medicine.
  • The study argues that regenerative medicine, specifically involving mesenchymal stromal cells (MSCs), might hold potential solutions for skin wound healing. These cells play a role in controlling the local inflammatory response and replacing cells.
  • The researchers used Wharton’s Jelly Mesenchymal Stem Cells (WJMSCs) derived from an equine umbilical cord. These cells were applied to a non-healing skin wound on a 6-month-old filly. These WJMSCs were applied through a carboxymethylcellulose (CMC) gel. This gel was produced by dissolving CMC in the horse’s plasma.

The Experiment and Findings

  • At the start of the experiment, the wound’s average area was 7.28 cm. After the final application of WJMSCs, the wound area decreased to an average of 1.90 cm, signaling a wound regression rate of 74%.
  • The treatment did not result in any local or systemic side effects, and there was no evident excessive scarring after the wound healed. The average wound area was further reduced to 0.38 cm at discharge, accounting for an 80% total regression rate.
  • The wound was completely healed five days after discharge. Therefore, they concluded that the utilization of WJMSCs resulted in promising clinical outcomes, potentially opening up future applications in treating chronic wounds in horses.

Cite This Article

APA
Lanci A, Merlo B, Mariella J, Castagnetti C, Iacono E. (2019). Heterologous Wharton’s Jelly Derived Mesenchymal Stem Cells Application on a Large Chronic Skin Wound in a 6-Month-Old Filly. Front Vet Sci, 6, 9. https://doi.org/10.3389/fvets.2019.00009

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 6
Pages: 9

Researcher Affiliations

Lanci, Aliai
  • Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
Merlo, Barbara
  • Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
Mariella, Jole
  • Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
Castagnetti, Carolina
  • Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
Iacono, Eleonora
  • Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.

References

This article includes 33 references
  1. Dart AJ, Dowling BA, Smith CL. Topical treatments in equine wound management. Vet Clin North Am Equine Pract (2005) 21:77–89.
    doi: 10.1016/j.cveq.2004.11.003pubmed: 15691601google scholar: lookup
  2. Theoret CL. Update on wound repair. Clin Tech Equine Pract (2004) 3:110–22.
    doi: 10.1053/j.ctep.2004.08.009google scholar: lookup
  3. Iacono E, Merlo B, Romagnoli N, Rossi B, Ricci F, Spadari A. Equine bone marrow and adipose tissue mesenchymal stem cells: cytofluorimetric characterization, in vitro differentiation and clinical application. J Equine Vet Sci (2015) 35:130–40.
    doi: 10.1016/j.jevs.2014.12.010google scholar: lookup
  4. Colleoni S, Bottani E, Tessaro I, Mari G, Merlo B, Romagnoli N. Isolation, growth and differentiation of equine mesenchymal stem cells: effect of door, source, amount of tissue and supplementation with basic fibroblast growth factor. Vet Res Commun (2009) 33:811–21.
    doi: 10.1007/s11259-009-9229-0pubmed: 19472068google scholar: lookup
  5. Guest DJ, Smith MR, Allen WR. Equine embryonic stem-like cells and mesenchymal stromal cells have different survival rates and migration patterns following their injection into damaged superficial digital flexor tendon. Equine Vet J (2010) 42:636–42.
    doi: 10.1111/j.2042-3306.2010.00112.xpubmed: 20840579google scholar: lookup
  6. Lange-Consiglio A, Corradetti B, Meucci A, Bizzaro D, Cremonesi F. Characteristics of equine mesenchymal stem cells derived from amnion and bone marrow: in vitro proliferative and multilineage potential assessment. Equine Vet J (2013) 45:737–44.
    doi: 10.1111/evj.12052pubmed: 23527626google scholar: lookup
  7. Paris DB, Stout TA. Equine embryos and embryonic stem cells: defining reliable markers of pluripotency. Theriogenology (2010) 74:516–24.
    doi: 10.1016/j.theriogenology.2009.11.020pubmed: 20071015google scholar: lookup
  8. De Coppi P, Bartsch G, Siddiqui MM, Xu T, Santos CC, Perin L. Isolation of amniotic stem cell lines with potential for therapy. Nature Biotech (2007) 25:100–06.
    doi: 10.1038/nbt1274pubmed: 17206138google scholar: lookup
  9. You Q, Cai L, Zheng J, Tong X, Zhang D, Zhang Y. Isolation of human mesenchymal stem cells from third-trimester amniotic fluid. Intern J Gynaecol Obstet (2008) 103:149–52.
    doi: 10.1016/j.ijgo.2008.06.012pubmed: 18760782google scholar: lookup
  10. Iacono E, Rossi B, Merlo B. Stem cells from foetal adnexa and fluid in domestic animals: an update on their features and clinical application. Reprod Dom Anim (2015) 50:353–64.
    doi: 10.1111/rda.12499pubmed: 25703812google scholar: lookup
  11. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res (2007) 106:971–80.
    doi: 10.1161/CIRCRESAHA.109.210682pmc: PMC4317351pubmed: 20110532google scholar: lookup
  12. Zubin E, Conti V, Leonardi F, Zanichelli S, Ramoni R, Grolli S. Regenerative therapy for the management of a large skin wound in a dog. Clin Case Rep (2015) 3:568–603.
    doi: 10.1002/ccr3.253pmc: PMC4527804pubmed: 26273450google scholar: lookup
  13. Spaas JH, Broeckx S, Van de Walle GR, Polettini M. The effects of equine peripheral blood stem cells on cutaneous wound healing: a clinical evaluation in four horses. Clin Exp Dermatol (2013) 38:280–84.
    doi: 10.1111/ced.12068pmc: PMC3627309pubmed: 23517358google scholar: lookup
  14. Martinello T, Gomiero C, Perazzi A, Iacopetti I, Gemignani F, DeBenedictis GM. Allogeneic mesenchymal stem cells imrpove the wound healing process of sheep skin. BMC Vet Res (2018) 14:202.
    doi: 10.1186/s12917-018-1527-8pmc: PMC6019727pubmed: 29940954google scholar: lookup
  15. Iacono E, Merlo B, Pirrone A, Antonelli C, Brunori L, Romagnoli N. Effects of mesenchymal stem cells isolated from amniotic fluid and platelet-rich plasma gel on severe decubitus ulcers in a septic neonatal foal. Res Vet Sci (2012) 93:1439–40.
    doi: 10.1016/j.rvsc.2012.04.008pubmed: 22579411google scholar: lookup
  16. Iacono E, Lanci A, Merlo B, Ricci F, Pirrone A, Antonelli C. Effects of amniotic fluid mesenchymal stem cells in carboxymethyl cellulose gel on spontaneous pressure sores healing: clinical outcome in seven hospitalized neonatal foals. Turkish J Biol (2016) 40:484–92.
    doi: 10.3906/biy-1507-147google scholar: lookup
  17. Ferrell B, Artinian B, Sessing D. The sessing scale for assessment of pressure ulcer healing. J Am Geriatr Soc (1995) 43:37–40.
    pubmed: 7806737
  18. Bluestein D, Javaheri A. Pressure ulcers: prevention, evaluation, and management. Am Fam Phys (2008) 78:1186–94.
    pubmed: 19035067
  19. Hendrickson DA. Management of superficial wounds. In: Auer JA, Stick JA. editors. Equine Surgery. St Louis, MO: Elsevier; (2012). p. 306–16.
  20. Iacono E, Pascucci L, Rossi B, Bazzucchi C, Lanci A, Ceccoli M. Ultrastructural characteristics and immune profile of equine MSCs from fetal adnexa. Reproduction (2017) 154:509–19.
    doi: 10.1530/REP-17-0032pubmed: 28733347google scholar: lookup
  21. Iacono E, Brunori L, Pirrone A, Ricci F, Pagliaro PP, Tazzari PL. Isolation, characterization and differentiation of mesenchymal stem cells (MSCs) from amniotic fluid, cord blood and Wharton's jelly in the horse. Reproduction (2012) 143:455–68.
    doi: 10.1530/REP-10-0408pubmed: 22274885google scholar: lookup
  22. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 8:315–7.
    doi: 10.1080/14653240600855905pubmed: 16923606google scholar: lookup
  23. Bertone AL. Management of exuberant granulation tissue. Vet Clin North Am Equine Pract (1989) 5:551–62.
    pubmed: 2691030
  24. Theoret CL. Wound repair in the horse: problems and innovative solutions. In: Stashak TS, Theoret CL. editors. Equine Wound Management. Indianapolis, IN: Wiley-Blackwell Press; (2008). p. 47–68.
  25. Knottenbelt D. Pascoe's Principles and Practice of Equine Dermatology. 2nd ed St. Louis, MI: Saunders Press; (2009).
  26. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood (2007) 110:3499–506.
    doi: 10.1182/blood-2007-02-069716pubmed: 17664353google scholar: lookup
  27. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med (2010) 16:203–9.
    doi: 10.1016/j.molmed.2010.02.005pmc: PMC2881950pubmed: 20335067google scholar: lookup
  28. Choi M, Lee HS, Naidansaren P, Kim HK, Cha JH, Ahn HY. Proangiogenic features of Wharton's jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels. Int J Biochem Cell Biol (2013) 45:560–70.
    doi: 10.1016/j.biocel.2012.12.001pubmed: 23246593google scholar: lookup
  29. Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS ONE (2013) 8:e72604.
    doi: 10.1371/journal.pone.0072604pmc: PMC3749979pubmed: 23991127google scholar: lookup
  30. Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol (2009) 259:150–6.
    doi: 10.1016/j.cellimm.2009.06.010pubmed: 19608159google scholar: lookup
  31. Ribeiro J, Pereira T, Amorim I, Caseiro AR, Lopes MA, Lima J. Cell therapy with human MSCs isolated from the umbilical cord wharton jelly associated to a PVA Membrane in the treatment of chronic skin wounds. Intern J Medical Sci (2014) 11:979–87.
    doi: 10.7150/ijms.9139pmc: PMC4115236pubmed: 25076843google scholar: lookup
  32. Rodrigues C, de Assis AM, Moura DJ, Halmenschlager G, Sa J, Xavier LL. New therapy of skin repair combining adipose-derived mesenchymal stem cells with sodium carboxymethylcellulose scaffold in a pre-clinical rat model. PLoS ONE (2014) 9:e96241.
    doi: 10.1371/journal.pone.0096241pmc: PMC4008527pubmed: 24788779google scholar: lookup
  33. Wonga TW, Ramli NA. Carboxymethylcellulose for bacterial wound infection control and healing. Carbohyd Polym (2014) 112:367–75.
    doi: 10.1016/j.carbpol.2014.06.002pubmed: 25129756google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.